Joleen Hubbard, MD
Medical Oncology · Rochester, MNNPI 1952351009
Payments from drug & device makers
Across 408 payments — averaging $4492.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$682K
- Amgen$243K
- Seagen Inc.$221K
- Incyte Corporation$170K
- G1 Therapeutics, Inc.$169K
- Taiho Oncology, Inc.$117K
- plus $232K from 11 others
What the payments were for
- Consulting fees$44,22675%
- Speaking & faculty fees$12,33021%
- Travel & lodging$1,1752%
- Food & beverage$1,4272%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 84 | $681,596 |
| Amgen | 3 | $242,887 |
| Seagen Inc. | 46 | $220,824 |
| Incyte Corporation | 171 | $169,552 |
| G1 Therapeutics, Inc. | 36 | $169,107 |
| Taiho Oncology, Inc. | 8 | $117,010 |
| Biontech SE | 15 | $68,517 |
| Mirati Therapeutics, Inc. | 3 | $59,120 |
| Merck | 8 | $41,361 |
| Bayer | 25 | $31,966 |
| Genentech, Inc. | 1 | $22,720 |
| Beone Medicines USA, Inc. | 1 | $2,400 |
| AstraZeneca | 1 | $2,050 |
| Eisai Inc. | 1 | $1,900 |
| Daiichi Sankyo Inc. | 1 | $1,451 |
| Histosonics, Inc. | 1 | $233 |
| Array Biopharma Inc | 3 | $153 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,832,846 in reported general payments places this provider in the 80th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 58 | $520 |
| Dexamethasone | 42 | $504 |
| Ondansetron Hcl | 52 | $318 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $146 |
| LoperamideLoperamide Hcl | 14 | $119 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Rochester
- Evanthia GalanisRochester$72.3M
- Frank SinicropeRochester$10.3M
- Harry YoonRochester$10.2M
- Konstantinos LeventakosRochester$9.6M
- Matthew BlockRochester$8.1M
- Keith BibleRochester$7.5M
- Jian CampianRochester$7.3M
- Katharine PriceRochester$7M
- Robert McWilliamsRochester$6.3M
- Elisabeth HeathRochester$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.